UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas
- 20 October 2026
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 662
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
This publication has 39 references indexed in Scilit:
- Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefitCancer Cell, 2025
- Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapyCancer Cell, 2025
- Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerAnnals of Oncology, 2024
- Recent advances in the mechanisms of development and the early diagnosis and treatment of esophageal cancerHolistic Integrative Oncology, 2023
- Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinomaCancer Cell, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Immune phenotypic linkage between colorectal cancer and liver metastasisCancer Cell, 2022
- Interpretation of somatic POLE mutations in endometrial carcinomaThe Journal of Pathology, 2019
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer TypesJAMA Oncology, 2019
- Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasCell Reports, 2018